无症状成人糖尿病患者筛查心力衰竭与外周动脉疾病是否必要?对2025年美国糖尿病协会《糖尿病诊疗标准》的评述
该评述基于筛查原则与已发表文献,评估2025年美国糖尿病协会《糖尿病诊疗标准》中关于无症状成人糖尿病患者筛查心力衰竭和外周动脉疾病的推荐。作者认为,使用利钠肽筛查心力衰竭缺乏稳健证据,NT-proBNP作为筛查试验在无症状成人中表现不佳,且治疗推荐模糊、成本高;使用踝肱指数筛查外周动脉疾病的推荐同样缺乏严谨科学证据,证据合并了其他有效筛查试验且推广性有限,无结果解读与治疗指导。
要点
- 2025年ADA标准推荐考虑用利钠肽筛查无症状成人糖尿病患者的心力衰竭。
- 2025年ADA标准推荐对≥65岁且伴微血管病变、足部并发症或终末器官损害的无症状糖尿病患者用踝肱指数筛查外周动脉疾病。
- 作者认为上述两项筛查推荐均缺乏充分的筛查原则与文献支持。
核心结论
- 作者认为,尽管通过筛查改善医疗的意图值得肯定,但2025年ADA标准中关于无症状成人糖尿病患者筛查心力衰竭和外周动脉疾病的推荐未得到筛查原则和已发表文献的充分支持。
- 作者认为ADA必须以最高的科学严谨性来制定其《糖尿病诊疗标准》。
研究设计与样本
- 本文为针对2025年美国糖尿病协会《糖尿病诊疗标准》中筛查推荐的评述,采用已建立的筛查原则和已发表文献进行评估。
主要发现
- 使用利钠肽筛查心力衰竭的推荐在多个关键领域缺乏稳健证据。
- NT-proBNP本身作为筛查试验在无症状成人中表现不佳。
- 在糖尿病和B期心力衰竭成人中,关于钠-葡萄糖协同转运蛋白2抑制剂治疗改善结局的证据不足,且治疗推荐存在模糊性。
- 筛查涉及的成本高,可能无法在经济上被证明合理。
- 使用踝肱指数筛查外周动脉疾病的推荐缺乏严谨科学证据,所引证据将ABI筛查与其他有效筛查试验合并,推广性有限。
关键数值与推荐
- 2025年ADA标准推荐临床医生考虑使用利钠肽水平筛查无症状成人糖尿病患者的心力衰竭。
- 2025年ADA标准推荐对≥65岁且伴任何微血管病变、足部并发症或糖尿病终末器官损害的无症状成人糖尿病患者,使用踝肱指数检测筛查外周动脉疾病。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The American Diabetes Association (ADA) publishes the "Standards of Care in Diabetes" (SOC) annually to offer clinicians, patients, and payers evidence-based guidelines for diabetes management. The 2025 SOC recommends that clinicians consider screening asymptomatic adults with diabetes for heart failure using natriuretic peptide levels, and that they screen asymptomatic adults with diabetes ≥65 years of age with any microvascular disease, foot complications, or end-organ damage from diabetes for peripheral artery disease (PAD) using ankle-brachial index (ABI) testing. This perspective evaluates those recommendations using established screening principles and the published literature. The recommendation to screen for heart failure using natriuretic peptide lacks robust evidence in several key areas. N-terminal pro-B-type natriuretic peptide, or NT-proBNP, itself performs poorly as a screening test in asymptomatic adults. Furthermore, there is ambiguity in treatment recommendations and insufficient evidence showing improved outcomes with sodium-glucose cotransporter 2 inhibitor treatment in adults with diabetes and stage B heart failure. Finally, the costs involved are high and may not be economically justifiable. Similarly, the recommendation to screen for PAD in asymptomatic adults with diabetes is not backed by rigorous scientific evidence. The evidence cited combines ABI screening with other effective screening tests and has limited generalizability. There is no guidance on how to interpret the results of ABI testing or how the information gained should be used to direct treatment. While the intent to improve health care through screening is commendable, these recommendations are inadequately supported by the principles of screening and the published literature. It is imperative that the ADA uses the greatest scientific rigor to prepare its SOC.
引用
- Herman WH, Kuo S. Is Screening for Heart Failure and Peripheral Artery Disease Warranted in Asymptomatic Adults With Diabetes? A Perspective on the 2025 American Diabetes Association "Standards of Care in Diabetes". Diabetes Care. 2025. PMID: 40504992. doi:10.2337/dci24-0103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。